Please see the Yescarta or Tecartus Summary of Product Characteristics, including the Patient Information Leaflet and the Healthcare Provider Educational Material, all of which can be obtained by contacting Kite, a Gilead Company, Medical Information at UKMed.Info@gilead.com or by telephone on +353 (0)21 482 5999.

The European Society for Blood and Marrow Transplantation (EBMT) is maintaining a registry for follow up of patients who received Yescarta or Tecartus. Additional information can be obtained from: registryhelpdesk@ebmt.org.

Yescarta, the Yescarta Logo, Tecartus, the Tecartus Logo, KITE, and the KITE Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc.
© 2022 Kite Pharma, Inc. | KITE_CT_EU_PC: v6.0 21 April 2026
UKI-TEC-0168 | Date of Preparation: October 2026

Kite
A GILEAD Company

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS

- This patient has received an engineered autologous T-cell immunotherapy product that can lead to severe and even fatal cytokine release syndrome and neurologic adverse reactions. Cytokine release syndrome may involve any organ system.
- WARNING: Cytokine release syndrome and neurologic adverse reactions. See Summary of Product Characteristics for full details.
- The treating healthcare professional must complete the Patient Card including the name of the product infused.

IMPORTANT INFORMATION FOR HEALTHCARE PROVIDERS (continued)

- Assess the patient for signs and symptoms of cytokine release syndrome and neurologic adverse reactions.
- See the Healthcare Provider Educational Material on how to manage cytokine release syndrome and neurologic adverse reactions.
- **Contact the patient's physician immediately for further information.**

Yescarta® ▼(axicabtagene ciloleucel) Dispersion for infusion
Tecartus® ▼ (brexucabtagene autoleucel) Dispersion for infusion

Patient Card

Product infused: *Write name of product infused*

▼These medicinal products are subject to additional monitoring.

Take this card with you if you go to the hospital or see any healthcare provider other than your treating healthcare provider.

Be sure to tell all healthcare providers you see that you are being treated with an autologous T-cell immunotherapy and SHOW THEM THIS CARD.

MY TREATING HEALTHCARE PROFESSIONAL CONTACT INFORMATION & DATE OF INFUSION

Name of treating healthcare professional:

Office phone:

After-hours phone:

My name and phone:

Product infused: *Write name of product infused*

Product batch number:

Date of infusion:

IMPORTANT REMINDERS FOR PATIENTS

- If you experience severe nausea, vomiting, diarrhoea, tiredness or any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare provider, or any healthcare provider available.
- Do not treat any of these symptoms with over-the-counter medications or herbal/dietary supplements without the approval of your treating healthcare provider.

IMPORTANT REMINDERS FOR PATIENTS (continued)

Write name of product infused can cause serious side effects in different parts of your body. These symptoms can be life-threatening or even fatal and need to be addressed immediately.

Symptoms that appear mild may quickly worsen.

Symptoms may be delayed and may occur weeks after your infusion.

Do not feel embarrassed or that you are inconveniencing your healthcare provider.

Patients must remain within the proximity of a qualified treatment centre or an appropriately trained clinical facility for at least 2 weeks following infusion.

Patients should carry this patient card at all times.

Call your treating healthcare provider right away if you have any of these symptoms

Neurologic Adverse Reactions
- Confusion
- Difficulty speaking
- Difficulty understanding speech
- Tremors (shaky arms or body parts)
- Agitation
- Increased sleepiness
- Dizziness

Cytokine Release Syndrome
- Fever (eg, temperature above 38°C)
- Tiredness
- Shortness of breath
- Low urine output
- Nausea
- Vomiting
- Diarrhoea
- Irregular heartbeat

You can report adverse drug reactions to the following email: **Safety_FC@gilead.com** or via the **www.gilead.com** website using the 'Report an Adverse Event' link.

Alternatively, reporting forms and information can be found at **www.hpra.ie**.